DUBLIN--(BUSINESS WIRE)--The "Competitor Analysis: PRAME-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.
This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
The report includes a compilation of currently active projects in research and development of passive and active immunotherapy and adoptive cell therapy targeting PRAME. In addition, the report lists company- and institution-specific R&D pipelines of PRAME-Targeted Immunotherapies.
PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma.
Subsequently, it has been shown that PRAME is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non-small cell lung cancer, and leukemia, whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium.
It was shown that PRAME-specific CD8+ T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- Additional comments with a hyperlink leading to the source of information
Key Topics Covered
1. PRAME-Targeted Immunotherapy
- PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
- PRAME-Selective Cellular & Recombinant Immunotherapies
- PRAME-Specific, Multi-Target Adoptive Cell Therapy
2. Corporate & Institutional PRAME Immunotherapy R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/n5txrb/2018_competitor?w=4